Symptomatic and quality of life response to tolterodine in subgroups of men with overactive bladder symptoms and presumed non-obstructive benign prostatic hyperplasia

• Published in: World journal of urology Vol. 28; no. 3; pp. 353 - 357
• Main Authors: Höfner, K., Burkart, M., Jacob, G., Jonas, U.
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer-Verlag 01-06-2010; Springer; Springer Nature B.V
• Subjects: Adrenergic alpha-Antagonists - administration & dosage; Age Factors; Aged; Benzhydryl Compounds - administration & dosage; Biological and medical sciences; Cresols - administration & dosage; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Humans; Male; Medical sciences; Medicine; Medicine & Public Health; Middle Aged; Muscarinic Antagonists - administration & dosage; Nephrology; Nephrology. Urinary tract diseases; Oncology; Original Article; Patient Satisfaction; Phenylpropanolamine - administration & dosage; Probability; Prospective Studies; Prostatic Hyperplasia - diagnosis; Prostatic Hyperplasia - drug therapy; Prostatism - diagnosis; Prostatism - drug therapy; Quality of Life; Regression Analysis; Severity of Illness Index; Statistics, Nonparametric; Tolterodine Tartrate; Treatment Outcome; Tumors of the urinary system; Urinary Bladder, Overactive - diagnosis; Urinary Bladder, Overactive - drug therapy; Urinary system involvement in other diseases. Miscellaneous; Urinary tract. Prostate gland; Urodynamics; Urology; Tolterodine ER; OAB; LUTS; Nephrology; Prostate disease; Male; Subgroup; Urology; Voiding dysfunction; Cholinergic receptor; Adult; Benign prostatic hyperplasia; Overactive bladder; Antagonist; Benign neoplasm; Male genital diseases; Lower urinary tract symptoms; Human; Urinary system disease; Tolterodine; Urinary tract disease; Quality of life; Symptomatology; Anticholinergic agent; Antimuscarinic agent; Bladder disease; Muscarinic receptor
• ISSN: 0724-4983; 1433-8726
• DOI: 10.1007/s00345-009-0460-7

Objectives
To investigate the symptomatic and quality of life (QoL) response to treatment with tolterodine extended release (ER) in subgroups of male patients with Overactive Bladder Syndrome (OAB) and LUTS suggestive of non-obstructive benign prostatic hyperplasia (BPH) according to age, symptom severity, diabetes mellitus status, and concomitant treatment for LUTS.
Methods
Patients treated with tolterodine ER 4 mg/day for OAB symptoms, alone or added to unsuccessful alpha-blocker treatment of ≥6 weeks duration, and presumed non-obstructive BPH (
Q
max
 ≥ 15 ml/s) were observed for 12 weeks in a non-interventional study. Patients completed the International Prostate Symptom Score (IPSS) and Overactive Bladder Questionnaire (OAB-q) at baseline and after 12 weeks.
Results
52.4% of 741 patients were aged ≤65 years; 4, 64, and 32% had mild, moderate, and severe symptoms, respectively, according to IPSS; 14% had diabetes mellitus, and in 42% tolterodine was added to alpha blockers. In the various subgroups, mean IPSS total scores improved by 2.8–11.1 points, IPSS QoL scores by 1.8–2.4 points, and all OAB-q subscores by more than 14 points. Only IPSS and OAB-q baseline scores had a relevant impact on changes during treatment, benefits were greatest in patients with more severe symptoms and bother.
Conclusions
In men with symptoms of OAB and LUTS suggestive of non-obstructive BPH of all IPSS severity classes, aged ≤65 years or above, with or without concomitant diabetes or alpha-blockers, symptoms and QoL improved markedly during treatment with tolterodine ER.